knowledge -WSS

knowledge

author：hotspot 2025-09-27 22:59:53 - browse：465

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： When a patient nears the end, a feared therapy can comfort

WSS

The drug industry has found itself all alone in Washington

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Dementia risk linked to living in disadvantaged areas: Study

Amylyx ALS drug fails large clinical trial

Former medical device CEO who sold dummy, plastic parts convicted of fraud

explore

knowledge

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

What it’s like to watch children die of measles

After affirmative action ruling, medical educators look to 'holistic review'

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

BioMarin wins approval for gene therapy to treat hemophilia A

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Duchenne breakthrough therapy leaves behind pioneering families

First medicine developed to treat MASH expected to be approved soon

Duchenne breakthrough therapy leaves behind pioneering families

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

explore

5 dead in mass shooting on Caribbean island of St. Vincent: Police

Sen. Paul opposes bill to ban Chinese biotechs

Sen. Paul opposes bill to ban Chinese biotechs

Precocious puberty in girls comes with mental health risks

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

US jobless claims fall again as labor market continues to flash strength

hotspot

focus

hotspot

focus